Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Two-Year, Three-Arm, Randomized, Double Masked, Multicenter, Phase III Study Assessing the Efficacy and Safety of Brolucizumab versus Aflibercept in Adult Patients with Visual Impairment due to Diabetic Macular Edema (KESTREL)

Trial Profile

A Two-Year, Three-Arm, Randomized, Double Masked, Multicenter, Phase III Study Assessing the Efficacy and Safety of Brolucizumab versus Aflibercept in Adult Patients with Visual Impairment due to Diabetic Macular Edema (KESTREL)

Status: Recruiting
Phase of Trial: Phase III

Latest Information Update: 05 Nov 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Brolucizumab (Primary) ; Aflibercept
  • Indications Diabetic macular oedema
  • Focus Registrational; Therapeutic Use
  • Acronyms KESTREL
  • Sponsors Novartis; Novartis Pharmaceuticals
  • Most Recent Events

    • 07 Dec 2018 Planned End Date changed from 5 Jul 2021 to 13 Aug 2021.
    • 07 Dec 2018 Planned primary completion date changed from 3 Aug 2020 to 11 Sep 2020.
    • 02 Oct 2018 Planned End Date changed from 12 Jul 2021 to 5 Jul 2021.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top